Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ME2 | P23368 | 2/20 | 0.43 |
| ▸ | ME1 | P48163 | 2/20 | 0.43 |
| ▸ | ME3 | Q16798 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210498 | 0.77 | HDAC6 (0.70) | HDAC6GRM5 | |
| SCHEMBL16100125 | 0.75 | PKM (0.55) | HDAC6ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL16100162 | 0.75 | GRM5 (0.40) | HDAC6KMT2AMEN1MAPTGRM5 | |
| SCHEMBL2524772 | 0.74 | HDAC6 (0.49) | HDAC6ALDH1A1KMT2AMAPT | |
| SCHEMBL16099461 | 0.73 | HDAC6 (0.41) | HDAC6ALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL12285743 | 0.73 | HDAC6 (0.52) | HDAC6NPC1POLBGRM5 | |
| SCHEMBL12210531 | 0.72 | HDAC6 (0.60) | HDAC6NPC1GRM5 | |
| SCHEMBL25413038 | 0.72 | HDAC6 (0.46) | HDAC6NPC1KMT2AMEN1 | |
| SCHEMBL7131839 | 0.72 | NPC1 (0.86) | NPC1TDP1FKBP1AALDH1A1POLB | |
| SCHEMBL12210588 | 0.71 | HDAC6 (1.00) | HDAC6KMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946223-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2011130163-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175614-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885NPC1 2742/4885TDP1 2411/4885 |
| US-20110251184-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC6 1/4885NPC1 2742/4885TDP1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.